| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to insulin and diabetes care in the Philippines
|
Eala, Michelle Ann B
|
|
|
10 |
1 |
p. 16
|
artikel
|
| 2 |
Childhood obesity: a growing pandemic
|
The Lancet Diabetes & Endocrinology,
|
|
|
10 |
1 |
p. 1
|
artikel
|
| 3 |
Correction to Lancet Diabetes Endocrinol 2022; 10: 58–74
|
|
|
|
10 |
1 |
p. e1
|
artikel
|
| 4 |
COVID-19 and diabetes in Africa: a lethal combination
|
Burki, Talha
|
|
|
10 |
1 |
p. 23
|
artikel
|
| 5 |
COVID-19 targets human adrenal glands
|
Kanczkowski, Waldemar
|
|
|
10 |
1 |
p. 13-16
|
artikel
|
| 6 |
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
|
Rossing, Peter
|
|
|
10 |
1 |
p. 24-34
|
artikel
|
| 7 |
Diabetes and the WHO Model List of Essential Medicines
|
Beran, David
|
|
|
10 |
1 |
p. 17-18
|
artikel
|
| 8 |
Diabetes and the WHO Model List of Essential Medicines
|
Etienne, Carissa F
|
|
|
10 |
1 |
p. 21
|
artikel
|
| 9 |
Diabetes and the WHO Model List of Essential Medicines
|
Khan, Farah N
|
|
|
10 |
1 |
p. 16-17
|
artikel
|
| 10 |
Diabetes and the WHO Model List of Essential Medicines
|
Reddy, Amulya
|
|
|
10 |
1 |
p. 20-21
|
artikel
|
| 11 |
Diabetes and the WHO Model List of Essential Medicines
|
Unnikrishnan, Ranjit
|
|
|
10 |
1 |
p. 19-20
|
artikel
|
| 12 |
Diabetes and the WHO Model List of Essential Medicines
|
Danne, Thomas
|
|
|
10 |
1 |
p. 18-19
|
artikel
|
| 13 |
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
|
Verma, Subodh
|
|
|
10 |
1 |
p. 35-45
|
artikel
|
| 14 |
Glycaemic management in diabetes: old and new approaches
|
Ceriello, Antonio
|
|
|
10 |
1 |
p. 75-84
|
artikel
|
| 15 |
Is the impact of add on heart failure therapy influenced by background therapy?
|
Rydén, Lars
|
|
|
10 |
1 |
p. 3-5
|
artikel
|
| 16 |
Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals
|
Braune, Katarina
|
|
|
10 |
1 |
p. 58-74
|
artikel
|
| 17 |
Opportunities and challenges in closed-loop systems in type 1 diabetes
|
Wilson, Leah M
|
|
|
10 |
1 |
p. 6-8
|
artikel
|
| 18 |
SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes
|
Cheng, Alice Y Y
|
|
|
10 |
1 |
p. 2-3
|
artikel
|
| 19 |
Telehealth for people with diabetes: poised for a new approach
|
Hood, Korey K
|
|
|
10 |
1 |
p. 8-10
|
artikel
|
| 20 |
The changing character of diabetes complications
|
Bellary, Srikanth
|
|
|
10 |
1 |
p. 5-6
|
artikel
|
| 21 |
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records
|
Pearson-Stuttard, Jonathan
|
|
|
10 |
1 |
p. 46-57
|
artikel
|
| 22 |
Viswanathan Mohan: a dynasty of diabetology
|
Power, Carl
|
|
|
10 |
1 |
p. 22
|
artikel
|
| 23 |
Youth-onset type 2 diabetes among First Nations young people in northern Australia: a retrospective, cross-sectional study
|
Titmuss, Angela
|
|
|
10 |
1 |
p. 11-13
|
artikel
|
Tijdschrift beschrijving